Stay updated with breaking news from Gregory Vidal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Experts on HR+/HER2- breast cancer review recent real-world data on CDK4/6 inhibitors and share excitement about first-line trials that have not yet read out.
Gregory Vidal, MD, PhD, presents ASCO 2023 data from the SONIA trial, which assessed the efficacy of CDK4/6 inhibitors when given as part of a combination with endocrine therapy (ET) in either the first- or second-line setting.
A comprehensive discussion on approaches to optimizing treatment selection and dosing in HR+/HER2- breast cancer.
Experts on HR+/HER2- breast cancer review data updates on adjuvant therapies from the 2023 ASCO Annual Meeting.
/PRNewswire/ -- At the 2023 ASCO annual meeting, investigators from OneOncology's clinical team will present Oral Abstracts using real-world data to evidence...